{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:27:51Z","timestamp":1790803671276,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:00:00Z","timestamp":1504569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:00:00Z","timestamp":1504569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s11912-017-0634-1","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T04:05:46Z","timestamp":1504584346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["CSF-1R Inhibitor Development: Current Clinical Status"],"prefix":"10.1007","volume":"19","author":[{"given":"Florent","family":"Peyraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"key":"634_CR1","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","volume":"119","author":"DA Hume","year":"2012","unstructured":"Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012;119:1810\u201320.","journal-title":"Blood"},{"key":"634_CR2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1073\/pnas.87.4.1377","volume":"87","author":"SA Ridge","year":"1990","unstructured":"Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci U S A. 1990;87:1377\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"634_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/0008-5472.CAN-07-3234","volume":"68","author":"RM Tamimi","year":"2008","unstructured":"Tamimi RM, Brugge JS, Freedman ML, Miron A, Iglehart JD, Colditz GA, et al. Circulating colony stimulating factor-1 (CSF1) and breast cancer risk. Cancer Res. 2008;68:18.","journal-title":"Cancer Res"},{"key":"634_CR4","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"QW Zhang","year":"2012","unstructured":"Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2012;7:e50946.","journal-title":"PLoS One"},{"key":"634_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103:690\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"634_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","volume":"22","author":"A Mantovani","year":"2010","unstructured":"Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231\u20137.","journal-title":"Curr Opin Immunol"},{"key":"634_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549\u201355.","journal-title":"Trends Immunol"},{"key":"634_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889\u201396.","journal-title":"Nat Immunol"},{"key":"634_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","volume":"23","author":"M De Palma","year":"2013","unstructured":"De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23:277\u201386.","journal-title":"Cancer Cell"},{"key":"634_CR10","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-06-1823","volume":"67","author":"JB Wyckoff","year":"2007","unstructured":"Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67:2649\u201356.","journal-title":"Cancer Res"},{"key":"634_CR11","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.ejca.2004.03.016","volume":"40","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004;40:1660\u20137.","journal-title":"Eur J Cancer"},{"key":"634_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","volume":"1","author":"DG DeNardo","year":"2011","unstructured":"DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54\u201367.","journal-title":"Cancer Discov"},{"key":"634_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0092-8674(85)80047-7","volume":"41","author":"CJ Sherr","year":"1985","unstructured":"Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell. 1985;41:665\u201376.","journal-title":"Cell"},{"key":"634_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.1154370","volume":"320","author":"H Lin","year":"2008","unstructured":"Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320:807\u201311.","journal-title":"Science"},{"key":"634_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nri2356","volume":"8","author":"JA Hamilton","year":"2008","unstructured":"Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533\u201344.","journal-title":"Nat Rev Immunol"},{"key":"634_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coi.2005.11.006","volume":"18","author":"V Chitu","year":"2006","unstructured":"Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006;18:39\u201348.","journal-title":"Curr Opin Immunol"},{"key":"634_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"\u2022\u2022 Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846\u201359. First report showing that treatment with an anti-CSF-1R antibody (RG7155) depletes TAMs from the tumor tissue of cancer patients across various tumor types.","journal-title":"Cancer Cell"},{"key":"634_CR18","doi-asserted-by":"publisher","first-page":"14293","DOI":"10.1038\/ncomms14293","volume":"8","author":"MF Cuccarese","year":"2017","unstructured":"Cuccarese MF, Dubach JM, Pfirschke C, Engblom C, Garris C, Miller MA, et al. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging. Nat Commun. 2017;8:14293.","journal-title":"Nat Commun"},{"key":"634_CR19","doi-asserted-by":"publisher","first-page":"e1089381","DOI":"10.1080\/2162402X.2015.1089381","volume":"5","author":"SF Ngiow","year":"2016","unstructured":"Ngiow SF, Meeth KM, Stannard K, Barkauskas DS, Bollag G, Bosenberg M, et al. Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma. Oncoimmunology. 2016;5:e1089381.","journal-title":"Oncoimmunology."},{"key":"634_CR20","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1158\/1078-0432.CCR-13-3033","volume":"20","author":"TS Kim","year":"2014","unstructured":"Kim TS, Cavnar MJ, Cohen NA, Sorenson EC, Greer JB, Seifert AM, et al. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin Cancer Res. 2014;20:2350\u201362.","journal-title":"Clin Cancer Res"},{"key":"634_CR21","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","volume":"73","author":"J Xu","year":"2013","unstructured":"Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73:2782\u201394.","journal-title":"Cancer Res"},{"key":"634_CR22","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19:1264\u201372.","journal-title":"Nat Med"},{"key":"634_CR23","doi-asserted-by":"publisher","first-page":"e26968","DOI":"10.4161\/onci.26968","volume":"2","author":"DC Strachan","year":"2013","unstructured":"Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology. 2013;2:e26968.","journal-title":"Oncoimmunology"},{"key":"634_CR24","unstructured":"Hambleton J, Zhou L, Rogers S, van Marle S, van Iersel T, Zanghi J, Masteller E, Baker K, Wong B. A phase 1 study of FPA008, an anti-colony stimulating factor 1 receptor (anti-CSF1R) antibody in healthy volunteers and subjects with rheumatoid arthritis (RA): preliminary results. ACR\/ARHP Annual Meeting; 2014, Abstract number: 1493."},{"key":"634_CR25","unstructured":"Zhou L, Sikorski R, Rogers S, Costin S, Korkosz M, Jaraczewska-Baumann M, \u00c9va PF, Rojkovich B, Bartalos J, Masteller E, Xiang H, Wong B, Hambleton J. A phase 1 study of FPA008, an anti-colony stimulating factor 1 receptor (anti-CSF1R) antibody in patients (pts) with rheumatoid arthritis (RA): preliminary results. ACR\/ARHP Annual Meeting; 2015, Abstract number: 2749."},{"key":"634_CR26","doi-asserted-by":"crossref","unstructured":"Gomez-Roca CA, Cassier PA, Italiano A, Cannarile M, Ries C, Brillouet A, et al. Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced\/metastatic solid tumors. J Clin Oncol. 2015;33","DOI":"10.1200\/jco.2015.33.15_suppl.3005"},{"key":"634_CR27","doi-asserted-by":"crossref","unstructured":"Anthony SP, Puzanov I, Lin PS, Nolop KB, West B, Hoff DDV. Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit. J Clin Oncol 2011;15 Suppl: 3093\u20133093.","DOI":"10.1200\/jco.2011.29.15_suppl.3093"},{"key":"634_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an ivy foundation early phase clinical trials consortium phase II study. Neuro-Oncology. 2016;18:557\u201364.","journal-title":"Neuro-Oncology"},{"key":"634_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/cncr.27758","volume":"119","author":"HC Toh","year":"2013","unstructured":"Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer. 2013;119:380\u20137.","journal-title":"Cancer"},{"key":"634_CR30","doi-asserted-by":"publisher","first-page":"CT137","DOI":"10.1158\/1538-7445.AM2016-CT137","volume":"76","author":"K Papadopoulos","year":"2016","unstructured":"Papadopoulos K, Gluck L, Martin LP, Olszanski AJ, Ngarmchamnanrith G, Rasmussen E, et al. Abstract CT137: first-in-human study of AMG 820, a monoclonal anti-CSF-1R (c-fms) antibody, in patients (pts) with advanced solid tumors. Cancer Res. 2016;76:CT137.","journal-title":"Cancer Res"},{"key":"634_CR31","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73:1128\u201341.","journal-title":"Cancer Res"},{"key":"634_CR32","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/0008-5472.SABCS-09-5076","volume":"69","author":"H Rugo","year":"2009","unstructured":"Rugo H, Lopez-Hernandez J, Gomez-Villanueva A, Gupta N, Qian J, Qin Q, et al. ABT-869 in combination with paclitaxel (P) as first-line treatment in patients (pts) with advanced breast cancer. Cancer Res. 2009;69:5076.","journal-title":"Cancer Res"},{"key":"634_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ygyno.2016.04.325","volume":"141","author":"R Wesolowski","year":"2016","unstructured":"Wesolowski R, Sharma N, West B, Coussens L, Marimuthu A, Pelayo M, et al. A phase Ib study of pexidartinib (PLX3397) and weekly paclitaxel in patients with advanced solid tumors including an ovarian cancer subset. Gynecol Oncol. 2016;141:121.","journal-title":"Gynecol Oncol"},{"key":"634_CR34","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/0008-5472.CAN-11-2684","volume":"72","author":"W Chen","year":"2012","unstructured":"Chen W, Ma T, Shen XN, Xia XF, Xu GD, Bai XL, et al. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res. 2012;72:1363\u201372.","journal-title":"Cancer Res"},{"key":"634_CR35","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1158\/1078-0432.CCR-13-2576","volume":"20","author":"PP Patwardhan","year":"2014","unstructured":"Patwardhan PP, Surriga O, Beckman MJ, de Stanchina E, Dematteo RP, Tap WD, et al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res. 2014;20:3146\u201358.","journal-title":"Clin Cancer Res"},{"key":"634_CR36","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/j.1464-410X.2010.09804.x","volume":"107","author":"N Nonomura","year":"2011","unstructured":"Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 2011;107:1918\u201322.","journal-title":"BJU Int"},{"key":"634_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature08782","volume":"464","author":"M Ammirante","year":"2010","unstructured":"Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464:302\u20135.","journal-title":"Nature"},{"key":"634_CR38","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/0008-5472.CAN-14-0992","volume":"75","author":"J Escamilla","year":"2015","unstructured":"Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res. 2015;75:950\u201362.","journal-title":"Cancer Res"},{"key":"634_CR39","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057\u201369.","journal-title":"Cancer Res"},{"key":"634_CR40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256\u201365.","journal-title":"J Natl Cancer Inst"},{"key":"634_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10911-010-9194-9","volume":"15","author":"SL Shiao","year":"2010","unstructured":"Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia. 2010;15:411\u201321.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"634_CR42","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1101\/gad.169029.111","volume":"25","author":"SL Shiao","year":"2011","unstructured":"Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011;25:2559\u201372.","journal-title":"Genes Dev"},{"key":"634_CR43","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/2326-6066.CIR-14-0232","volume":"3","author":"SL Shiao","year":"2015","unstructured":"Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM. TH2-polarized CD4(+) T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol Res. 2015;3:518\u201325.","journal-title":"Cancer Immunol Res"},{"key":"634_CR44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00256-006-0249-3","volume":"36","author":"BP Rubin","year":"2007","unstructured":"Rubin BP. Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesions. Skelet Radiol. 2007;36:267\u20138.","journal-title":"Skelet Radiol"},{"key":"634_CR45","first-page":"413","volume":"7","author":"RC Martin 2nd","year":"2000","unstructured":"Martin RC 2nd, Osborne DL, Edwards MJ, Wrightson W, McMasters KM. Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence. Oncol Rep. 2000;7:413\u20139.","journal-title":"Oncol Rep"},{"key":"634_CR46","first-page":"547","volume":"29","author":"B Molena","year":"2011","unstructured":"Molena B, Sfriso P, Oliviero F, Pagnin E, Teramo A, Lunardi F, et al. Synovial colony-stimulating factor-1 mRNA expression in diffuse pigmented villonodular synovitis. Clin Exp Rheumatol. 2011;29:547\u201350.","journal-title":"Clin Exp Rheumatol"},{"key":"634_CR47","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1148\/rg.285085134","volume":"28","author":"MD Murphey","year":"2008","unstructured":"Murphey MD, Rhee JH, Lewis RB, Fanburg-Smith JC, Flemming DJ, Walker EA. Pigmented villonodular synovitis: radiologic-pathologic correlation. Radiographics. 2008;28:1493\u2013518.","journal-title":"Radiographics"},{"key":"634_CR48","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/CCO.0b013e328347e1e3","volume":"23","author":"V Ravi","year":"2011","unstructured":"Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol. 2011;23:361\u20136.","journal-title":"Curr Opin Oncol"},{"key":"634_CR49","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2217\/fon.13.124","volume":"9","author":"FG Verspoor","year":"2013","unstructured":"Verspoor FG, van der Geest IC, Vegt E, Veth RP, van der Graaf WT, Schreuder HW. Pigmented villonodular synovitis: current concepts about diagnosis and management. Future Oncol. 2013;9:1515\u201331.","journal-title":"Future Oncol"},{"key":"634_CR50","doi-asserted-by":"crossref","unstructured":"Schwartz HS, Unni KK, Pritchard DJ. Pigmented villonodular synovitis. A retrospective review of affected large joints. Clin Orthop Relat Res. 1989:243\u201355.","DOI":"10.1097\/00003086-198910000-00034"},{"key":"634_CR51","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdn033","volume":"19","author":"JY Blay","year":"2008","unstructured":"Blay JY, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodular synovitis\/tenosynovial giant cell tumor (PVNS\/TGCT). Ann Oncol. 2008;19:821\u20132.","journal-title":"Ann Oncol"},{"key":"634_CR52","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.26409","volume":"118","author":"PA Cassier","year":"2012","unstructured":"Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis. Cancer. 2012;118:1649\u201355.","journal-title":"Cancer"},{"key":"634_CR53","doi-asserted-by":"crossref","unstructured":"Gelderblom H, P\u00e9rol D, Chevreau C, Tattersall MH, Stacchiotti S, Casali PG, et al. An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. J Clin Oncol. 2013;31","DOI":"10.1200\/jco.2013.31.15_suppl.10516"},{"key":"634_CR54","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"\u2022\u2022 Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373:428\u201337. First report showing that CSF-1R blockade with a specific tyrosine kinase inhibitor is associated with significant anti-tumor activity in PVNS patients.","journal-title":"N Engl J Med"},{"key":"634_CR55","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","volume":"16","author":"PA Cassier","year":"2015","unstructured":"\u2022\u2022 Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16:949\u201356. First report showing that treatment with an anti-CSF-1R antibody (RG7155) is associated with significant anti-tumor activity in PVNS patients.","journal-title":"Lancet Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-017-0634-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-017-0634-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-017-0634-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:58:34Z","timestamp":1659092314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-017-0634-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1007\/s11912-017-0634-1","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]},"assertion":[{"value":"5 September 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Florent Peyraud, Sophie Cousin, and Antoine Italiano declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"70"}}